Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC1A2 | P43004 | 4/20 | 0.40 |
| ▸ | SLC1A3 | P43003 | 3/20 | 0.40 |
| ▸ | SLC1A1 | P43005 | 3/20 | 0.40 |
| ▸ | CPB2 | Q96IY4 | 5/20 | 0.38 |
| ▸ | BLM | P54132 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | GABRR1 | P24046 | 2/20 | 0.34 |
| ▸ | GRIK1 | P39086 | 2/20 | 0.34 |
| ▸ | GRIK2 | Q13002 | 2/20 | 0.34 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.33 |
| ▸ | CPT2 | P23786 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3966129 | 0.80 | CHRM1 (0.40) | SLC1A2SLC1A3SLC1A1CPB2CA2 | |
| SCHEMBL3996075 | 0.80 | CPB2 (0.50) | SLC1A2SLC1A3SLC1A1CPB2BLM | |
| Hydrochloric Acid SCHEMBL3994474 | 0.79 | CHRM1 (0.39) | SLC1A2SLC1A3SLC1A1CPB2CA2 | |
| SCHEMBL12391770 | 0.75 | CPB2 (0.40) | SLC1A2SLC1A3SLC1A1CPB2CA2 | |
| SCHEMBL977889 | 0.73 | SLC1A3 (0.61) | SLC1A2SLC1A3SLC1A1CPB2BLM | |
| SCHEMBL5378219 | 0.73 | SLC1A3 (0.61) | SLC1A2SLC1A3SLC1A1CPB2BLM | |
| SCHEMBL2904702 | 0.72 | CHRM1 (0.52) | SLC1A2SLC1A3SLC1A1CPB2BLM | |
| SCHEMBL4990488 | 0.72 | CA2 (0.48) | SLC1A2SLC1A3SLC1A1CPB2CA2 | |
| SCHEMBL3964216 | 0.72 | FFAR1 (0.37) | SLC1A2SLC1A3SLC1A1BLMFFAR1 | |
| SCHEMBL27658554 | 0.72 | FFAR1 (0.37) | SLC1A2SLC1A3SLC1A1BLMFFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1658059-A1 | A PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF OBESITY OR TO FACILITATE OR PROMOTE WEIGHT LOSS | Pfizer Products Inc. (US) | 2006-05-24 | — | — | EP | claimed |
| EP-1658058-A1 | A PHARMACEUTICAL COMPOSITION FOR THE PREVENTION AND TREATMENT OF ADDICTION IN A MAMMAL | Pfizer Products Inc. (US) | 2006-05-24 | — | — | EP | claimed |
| EP-1658098-A1 | PHARMACEUTICAL COMPOSITION COMPRISING AN ALPHA2DELTA LIGAND AND AN OPIOID RECEPTOR ANTAGONIST FOR THE PREVENTION AND TREATMENT OF ADDICTION IN A MAMMAL | Pfizer Products Inc. (US) | 2006-05-24 | — | — | EP | claimed |
| EP-1614675-A2 | Amino acids with affinity for the alpha-2-delta protein | Warner-Lambert Company LLC (US) | 2006-01-11 | — | — | EP | claimed |
| US-20050272783-A1 | Amino acids with affinity for the alpha2delta-protein | BARTA NANCY SUE | 2005-12-08 | — | — | US | claimed |
| WO-2005018622-A1 | A PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF OBESITY OR TO FACILITATE OR PROMOTE WEIGHT LOSS | PFIZER PRODUCTS INC. (US) | 2005-03-03 | — | — | WO | claimed |
| WO-2005018621-A1 | A PHARMACEUTICAL COMPOSITION FOR THE PREVENTION AND TREATMENT OF ADDICTION IN A MAMMAL | PFIZER PRODUCTS INC. (US) | 2005-03-03 | — | — | WO | claimed |
| WO-2005018670-A1 | PHARMACEUTICAL COMPOSITION COMPRISING AN ALPHA2DELTA LIGAND AND AN OPIOID RECEPTOR ANTAGONIST FOR THE PREVENTION AND TREATMENT OF ADDICTION IN A MAMMAL | PFIZER PRODUCTS INC. (US) | 2005-03-03 | — | — | WO | claimed |
| US-20050043407-A1 | Pharmaceutical composition for the prevention and treatment of addiction in a mammal | PFIZER INC | 2005-02-24 | — | — | US | claimed |
| US-20050043406-A1 | Pharmaceutical composition for the treatment of obesity or to facilitate or promote weight loss | PFIZER INC | 2005-02-24 | — | — | US | claimed |
| US-20050043345-A1 | Pharmaceutical composition for the prevention and treatment of addiction in a mammal | PFIZER INC | 2005-02-24 | — | — | US | claimed |
| US-20030195251-A1 | Amino acids with affinity for the alpha-2-delta-protein | BARTA NANCY SUE (US) | 2003-10-16 | — | — | US | claimed |
| US-7517909-B2 | Amino acids with affinity for the α2δ-protein | PFIZER INC (US) | 2009-04-14 | — | — | US | disclosed |
| US-20090036487-A1 | Combinations | PFIZER INC. | 2009-02-05 | — | — | US | disclosed |
| US-7419981-B2 | Synergistic combinations of an alpha-2-delta ligand and a cGMP phosphodieterse 5 inhibitor | PFIZER INC. (US) | 2008-09-02 | — | — | US | disclosed |
| EP-1536782-B1 | SYNERGISTIC COMBINATION OF AN ALPHA-2-DELTA LIGAND AND A PDEV INHIBITOR FOR USE IN THE TREATMENT OF PAIN | PFIZER LTD (GB) | 2007-04-18 | — | — | EP | disclosed |
| US-20040092522-A1 | Synergistic combinations | FIELD MARK JOHN (GB) | 2004-05-13 | — | — | US | disclosed |
| WO-2004016259-A1 | SYNERGISTIC COMBINATION OF AN ALPHA-2-DELTA LIGAND AND A PDEV INHIBITOR FOR USE IN THE TREATMENT OF PAIN | PFIZER LIMITED (GB) | 2004-02-26 | — | — | WO | disclosed |
| US-20030195251-A1 | Amino acids with affinity for the alpha-2-delta-protein | BARTA NANCY SUE (US) | 2003-10-16 | — | — | US | disclosed |
| WO-2003082807-A2 | AMINO ACIDS WITH AFFINITY FOR THE ALPHA-2-DELTA-PROTEIN | WARNER-LAMBERT COMPANY LLC (US) | 2003-10-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090036487-A1 | Combinations | CHRNE, CHRND, CHRNG | SLC1A2 423/4885SLC1A3 903/4885SLC1A1 1090/4885 |
| US-20040092522-A1 | Synergistic combinations | PDE2A, PDE1B, PDE1A | SLC1A2 788/4885SLC1A3 1462/4885SLC1A1 1311/4885 |
| US-20030195251-A1 | Amino acids with affinity for the alpha-2-delta-protein | SCN2A, OPRD1, CAMK2A | SLC1A2 19/4885SLC1A3 73/4885SLC1A1 67/4885 |
| US-20050272783-A1 | Amino acids with affinity for the alpha2delta-protein | SCN2A, OPRD1, SCN1A | SLC1A2 21/4885SLC1A3 83/4885SLC1A1 80/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.